Stock Comparison

NUVB vs UNH

Nuvation Bio Inc vs UnitedHealth Group Inc

The Verdict

NUVB takes this one.

Winner

NUVB

Nuvation Bio Inc

8.7

out of 10

Hidden Gem

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

$1.6B

Market Cap

$276.2B

-7.7

P/E Ratio

22.9

-325.3%

Profit Margin

2.7%

0.0%

Return on Equity

12.5%

0.2

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate-High

8.7

DVR Score

0.3

The Deep Dive

NUVB8.7/10

Nuvation Bio (NUVB) sustains its high 10x growth potential, reflecting robust progress in its transformation to a commercial-stage oncology firm. The Q4 2025 revenue beat and initial IBTROZI® product revenue of $24.7M with 216 new patient starts validate its commercial launch. Furthermore, the EMA's validation of taletrectinib's marketing application and upcoming pivotal data presentation at AACR ...

Full NUVB Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.